Clinical therapeutics for phenylketonuria

Drug Delivery and Translational Research

Volumn 2, Issue 4, 2012, Pages 223-237

  Kochhar, Jaspreet Singh ^a   Chan, Sui Yung ^a   Ong, Pei Shi ^a   Kang, Lifeng ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Hyperphenylalaninemia; Phenylalanine; Phenylalanine ammonia lyase; Phenylalanine hydroxylase; Phenylketonuria

Indexed keywords

2,4 BIS(O METHOXYPOLYETHYLENEGLYCOL) 6 CHLORO STRIAZINE; ADENOASSOCIATED VIRUS VECTOR 2; ADENOASSOCIATED VIRUS VECTOR 5; ADENOASSOCIATED VIRUS VECTOR 8; AMINO ACID DERIVATIVE; CALCIUM ALGINATE; GLYCOPROTEIN; MACROGOL; PARVOVIRUS VECTOR; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE; PHENYLALANINE AMMONIA LYASE; PLASMID DNA; SAPROPTERIN; SMALL INTERFERING RNA; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG;

BEHAVIOR DISORDER; COGNITIVE DEFECT; DIET RESTRICTION; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG FORMULATION; ENCAPSULATION; ENZYME REPLACEMENT; GENE MUTATION; HUMAN; INBORN ERROR OF METABOLISM; MICROCAPSULE; MOTOR DYSFUNCTION; NONHUMAN; PATHOPHYSIOLOGY; PHENYLKETONURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

EID: 84866158897     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0067-1     Document Type: Review

References (178)

1. Christ SE. Asbjorn Folling and the discovery of phenylketonuria. J Hist Neurosci. 2003; 12(1): 44-54.
2. Kwok SC, Ledley FD, DiLella AG, Robson KJ, Woo SL. Nucleotide sequence of a full-length complementary DNA clone and amino acid sequence of human phenylalanine hydroxylase. Biochemistry. 1985; 24(3): 556-61.
3. Scriver CR, Waters PJ, Sarkissian C, Ryan S, Prevost L, Cote D, et al. PAHdb: a locus-specific knowledgebase. Hum Mutat. 2000; 15(1): 99-104.
4. Scriver CR, Hurtubise M, Konecki D, Phommarinh M, Prevost L, Erlandsen H, et al. PAHdb 2003: what a locus-specific knowledgebase can do. Hum Mutat. 2003; 21(4): 333-44.
5. Kaufman S. A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients. Proc Natl Acad Sci USA. 1999; 96(6): 3160-4.
6. Daubner SC, Le T, Wang S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 2011; 508(1): 1-12.
7. Kim W, Erlandsen H, Surendran S, Stevens RC, Gamez A, Michols-Matalon K, et al. Trends in enzyme therapy for phenylketonuria. Mol Ther. 2004; 10(2): 220-4.
8. de Baulny HO, Abadie V, Feillet F, de Parscau L. Management of phenylketonuria and hyperphenylalaninemia. J Nutr. 2007; 137(6 Suppl 1): 1561S-3S. discussion 1573S-1575S.
9. Harding CO. Progress toward cell-directed therapy for phenylketonuria. Clin Genet. 2008; 74(2): 97-104.
10. Heintz C, Troxler H, Martinez A, Thony B, Blau N. Quantification of phenylalanine hydroxylase activity by isotope-dilution liquid chromatography-electrospray ionization tandem mass spectrometry. Mol Genet Metab. 2012; 105(4): 559-65.
11. Thony B, Blau N. Mutations in the BH4-metabolizing genes GTP cyclohydrolase I, 6-pyruvoyl-tetrahydropterin synthase, sepiapterin reductase, carbinolamine-4a-dehydratase, and dihydropteridine reductase. Hum Mutat. 2006; 27(9): 870-8.
12. Sarkissian CN, Scriver CR, Mamer OA. Measurement of phenyllactate, phenylacetate, and phenylpyruvate by negative ion chemical ionization-gas chromatography/mass spectrometry in brain of mouse genetic models of phenylketonuria and non-phenylketonuria hyperphenylalaninemia. Anal Biochem. 2000; 280(2): 242-9.
13. Eavri R, Lorberboum-Galski H. Novel approaches to the therapy of phenylketonuria. Ann Nestle. 2010; 68(2): 70-7.
14. Sanayama Y, Okano Y, Nagasaka H, Takayanagi M, Ohura T, Sakamoto O, et al. Experimental evidence that phenylalanine is strongly associated to oxidative stress in adolescents and adults with phenylketonuria. Mol Genet Metab. 2011; 103(3): 220-5.
15. Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: an inborn error of phenylalanine metabolism. Clin Biochem Rev. 2008; 29(1): 31-41.
16. van Spronsen FJ. Phenylketonuria: a 21st century perspective. Nat Rev Endocrinol. 2010; 6(9): 509-14.
17. Anonymous. Recommendations on the dietary management of phenylketonuria. Report of Medical Research Council Working Party on Phenylketonuria. Arch Dis Child. 1993; 68(3): 426-7.
18. Burgard P, Bremer HJ, Buhrdel P, Clemens PC, Monch E, Przyrembel H, et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr. 1999; 158(1): 46-54.
19. Schweitzer-Krantz S, Burgard P. Survey of national guidelines for the treatment of phenylketonuria. Eur J Pediatr. 2000; 159 Suppl 2: S70-3.
20. Feillet F, van Spronsen FJ, MacDonald A, Trefz FK, Demirkol M, Giovannini M, et al. Challenges and pitfalls in the management of phenylketonuria. Pediatrics. 2010; 126(2): 333-41.
21. Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010; 376(9750): 1417-27.
22. Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. Lancet. 1953; 265(6790): 812.
23. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics. 1963; 32: 338-43.
24. Bodamer OA. Screening for phenylketonuria. Ann Nestle. 2010; 68(2): 53-7.
25. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis. 1990; 13(3): 321-4.
26. Levy H, Burton B, Cederbaum S, Scriver C. Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment. Mol Genet Metab. 2007; 92(4): 287-91.
27. Blau N, Belanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, et al. Optimizing the use of sapropterin (BH(4)) in the management of phenylketonuria. Mol Genet Metab. 2009; 96(4): 158-63.
28. Ponzone A, Guardamagna O, Spada M, Ferraris S, Ponzone R, Kierat L, et al. Differential diagnosis of hyperphenylalaninaemia by a combined phenylalanine-tetrahydrobiopterin loading test. Eur J Pediatr. 1993; 152(8): 655-61.
29. Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011; 104(Suppl): S2-9.
30. Jaggi L, Zurfluh MR, Schuler A, Ponzone A, Porta F, Fiori L, et al. Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab. 2008; 93(3): 295-305.
31. Millington DS, Sista R, Eckhardt A, Rouse J, Bali D, Goldberg R, et al. Digital microfluidics: a future technology in the newborn screening laboratory? Semin Perinatol. 2010; 34(2): 163-9.
32. Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics. 1998; 102(6): E69.
33. American College of Medical Genetics and Genomics (ACMG). 2011. http://www. acmg. net/StaticContent/ACT/Algorithms/Visio-Phenylalanine. pdf. Accessed 6 July 2011.
34. National Institutes of Health (NIH) US. 2011. http://www. clinicaltrials. gov/ct2/results?term=Phenylketonuria+AND+phenylalanine+ammonia+lyase. Accessed 26 April 2012.
35. van Spronsen FJ, Enns GM. Future treatment strategies in phenylketonuria. Mol Genet Metab. 2010; 99 Suppl 1: S90-5.
36. Sarkissian CN, Gamez A, Scriver CR. What we know that could influence future treatment of phenylketonuria. J Inherit Metab Dis. 2009; 32(1): 3-9.
37. Sarkissian CN, Gamez A. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now? Mol Genet Metab. 2005; 86 Suppl 1: S22-6.
38. Woolf LI, Griffiths R, Moncrieff A. Treatment of phenylketonuria with a diet low in phenylalanine. Br Med J. 1955; 1(4905): 57-64.
39. Armstrong MD, Tyler FH. Studies on phenylketonuria. I. Restricted phenylalanine intake in phenylketonuria. J Clin Invest. 1955; 34(4): 565-80.
40. Smith I, Wolff OH. Natural history of phenylketonuria and influence of early treatment. Lancet. 1974; 2(7880): 540-4.
41. Mikoluc B, Witalis E, Jastrzebska-Piotrowska J, Wojcicka-Bartlomiejczyk B, Nowacka M, Starostecka E, et al. Diet compliance in patients with phenylketonuria (PKU)-influencing factors. J Inherit Metab Dis. 2006; 29: 51.
42. MacDonald A. Diet and compliance in phenylketonuria. Eur J Pediatr. 2000; 159: S136-41.
43. Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, et al. How practical are recommendations for dietary control in phenylketonuria? Lancet. 2002; 360(9326): 55-7.
44. Cotugno G, Nicolo R, Cappelletti S, Goffredo B, Dionisi Vici C, Di Ciommo V. Adherence to diet and quality of life in patients with phenylketonuria. Acta Paediatr. 2011; 100(8): 1144-9.
45. Simon E, Schwarz M, Roos J, Dragano N, Geraedts M, Siegrist J, et al. Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU). Health Qual Life Outcomes. 2008; 6: 25.
46. Landolt MA, Nuoffer JM, Steinmann B, Superti-Furga A. Quality of life and psychologic adjustment in children and adolescents with early treated phenylketonuria can be normal. J Pediatr. 2002; 140(5): 516-21.
47. ten Hoedt AE, de Sonneville LM, Francois B, ter Horst NM, Janssen MC, Rubio-Gozalbo ME, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis. 2011; 34(1): 165-71.
48. Mutze U, Roth A, Weigel JF, Beblo S, Baerwald CG, Buhrdel P, et al. Transition of young adults with phenylketonuria from pediatric to adult care. J Inherit Metab Dis. 2011; 34(3): 701-9.
49. Smith I, Beasley MG, Ades AE. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child. 1990; 65(5): 472-8.
50. Acosta PB, Yannicelli S, Singh T, Eisas LJ, Kennedy MJ, Bernstein L, et al. Intake and blood levels of fatty acids in treated patients with phenylketonuria. J Pediatr Gastr Nutr. 2001; 33(3): 253-9.
51. Acosta PB, Yannicelli S, Singh R, Mofidi S, Steiner R, DeVincentis E, et al. Nutrient intakes and physical growth of children with phenylketonuria undergoing nutrition therapy. J Am Diet Assoc. 2003; 103(9): 1167-73.
52. Acosta PB, Yannicelli S, Singh RH, Elsas LJ, Mofidi S, Steiner RD. Iron status of children with phenylketonuria undergoing nutrition therapy assessed by transferrin receptors. Genet Med. 2004; 6(2): 96-101.
53. Schwahn B, Mokov E, Scheidhauer K, Lettgen B, Schonau E. Decreased trabecular bone mineral density in patients with phenylketonuria measured by peripheral quantitative computed tomography. Acta Paediatr. 1998; 87(1): 61-3.
54. Cockburn F, Clark BJ, Caine EA, Harvie A, Farquharson J, Jamieson EC, et al. Fatty acids in the stability of neuronal membrane: relevance to PKU. Int Pediatr. 1996; 11(1): 56-60.
55. Koch R, Hanley W, Levy H, Matalon R, Rouse B, Trefz F, et al. Maternal phenylketonuria: an international study. Mol Genet Metab. 2000; 71(1-2): 233-9.
56. Cockburn F, Clark BJ. Recommendations for protein and amino acid intake in phenylketonuric patients. Eur J Pediatr. 1996; 155: S125-9.
57. National Institutes of Health Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000. Pediatrics. 2001; 108(4): 972-82.
58. Werner ER, Blau N, Thony B. Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J. 2011; 438(3): 397-414.
59. Blaskovics MS, Schaeffl GE, Hack S. Phenylalaninaemia-differential diagnosis. Arch Dis Child. 1974; 49(11): 835-43.
60. Longo N. Disorders of biopterin metabolism. J Inherit Metab Dis. 2009; 32(3): 333-42.
61. Blau N, Thöny B, Cotton RGH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, editors. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2001. p. 1725-76.
62. Blau N, Thony B, Spada M, Ponzone A. Tetrahydrobiopterin and inherited hyperphenylalaninemias. Turkish J Pediatr. 1996; 38(1): 19-35.
63. Danks DM, Bartholome K, Clayton BE. Malignant hyperphenylalaninaemia. Current status (June 1977). J Inherit Metab Dis. 1978; 1(2): 49-53.
64. Kure S, Hou DC, Ohura T, Iwamoto H, Suzuki S, Sugiyama N, et al. Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr. 1999; 135(3): 375-8.
65. Muntau AC, Roschinger W, Habich M, Demmelmair H, Hoffmann B, Sommerhoff CP, et al. Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. New Engl J Med. 2002; 347(26): 2122-32.
66. Blau N, Erlandsen H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab. 2004; 82(2): 101-11.
67. Gersting SW, Kemter KF, Staudigl M, Messing DD, Danecka MK, Lagler FB, et al. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am J Hum Genet. 2008; 83(1): 5-17.
68. Erlandsen H, Pey AL, Gamez A, Perez B, Desviat LR, Aguado C, et al. Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci USA. 2004; 101(48): 16903-8.
69. Kure S, Sato K, Fujii K, Aoki Y, Suzuki Y, Kato S, et al. Wild-type phenylalanine hydroxylase activity is enhanced by tetrahydrobiopterin supplementation in vivo: an implication for therapeutic basis of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab. 2004; 83(1-2): 150-6.
70. Muntau AC, Gersting SW. Phenylketonuria as a model for protein misfolding diseases and for the development of next generation orphan drugs for patients with inborn errors of metabolism. J Inherit Metab Dis. 2010; 33(6): 649-58.
71. Aguado C, Perez B, Ugarte M, Desviat LR. Analysis of the effect of tetrahydrobiopterin on PAH gene expression in hepatoma cells. FEBS Lett. 2006; 580(7): 1697-701.
72. Pey AL, Perez B, Desviat LR, Martinez MA, Aguado C, Erlandsen H, et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum Mutat. 2004; 24(5): 388-99.
73. Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, Thony B, et al. Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest. 2008; 118(8): 2858-67.
74. Perez B, Desviat LR, Gomez-Puertas P, Martinez A, Stevens RC, Ugarte M. Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients. Mol Genet Metab. 2005; 86 Suppl 1: S11-6.
75. Ames BN, Elson-Schwab I, Silver EA. High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased K-m): relevance to genetic disease and polymorphisms. Am J Clin Nutr. 2002; 75(4): 616-58.
76. Hegge KA, Horning KK, Peitz GJ, Hegge K. Sapropterin: a new therapeutic agent for phenylketonuria. Ann Pharmacother. 2009; 43(9): 1466-73.
77. Levy HL, Milanowski A, Chakrapani A, Cleary M, Lee P, Trefz FK, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. Lancet. 2007; 370(9586): 504-10.
78. Burton BK, Grange DK, Milanowski A, Vockley G, Feillet F, Crombez EA, et al. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study. J Inherit Metab Dis. 2007; 30(5): 700-7.
79. Giugliani L, Sitta A, Vargas CR, Santana-da-Silva LC, Nalin T, Saraiva-Pereira ML, et al. Tetrahydrobiopterin responsiveness of patients with phenylalanine hydroxylase deficiency. J Pediatr (Rio J). 2011; 87(3): 245-51.
80. Sanford M, Keating GM. Sapropterin a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs. 2009; 69(4): 461-76.
81. Burton BK, Nowacka M, Hennermann JB, Lipson M, Grange DK, Chakrapani A, et al. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study. Mol Genet Metab. 2011; 103(4): 315-22.
82. MacDonald A, Ahring K, Dokoupil K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, et al. Adjusting diet with sapropterin in phenylketonuria: what factors should be considered? Br J Nutr. 2011; 106(2): 175-82.
83. Burton BK, Bausell H, Katz R, Laduca H, Sullivan C. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol Genet Metab. 2010; 101(2-3): 110-4.
84. Burton BK, Adams DJ, Grange DK, Malone JI, Jurecki E, Bausell H, et al. Tetrahydrobiopterin therapy for phenylketonuria in infants and young children. J Pediatr. 2011; 158(3): 410-5.
85. Trefz FK, Burton BK, Longo N, Casanova MM, Gruskin DJ, Dorenbaum A, et al. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr. 2009; 154(5): 700-7.
86. Bik-Multanowski M, Pietrzyk JJ. Blood phenylalanine clearance and BH(4)-responsiveness in classic phenylketonuria. Mol Genet Metab. 2011; 103(4): 399-400.
87. Fiege B, Ballhausen D, Kierat L, Leimbacher W, Goriounov D, Schircks B, et al. Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab. 2004; 81(1): 45-51.
88. Trefz FK, Belanger-Quintana A. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria. Drugs Today (Barc). 2010; 46(8): 589-600.
89. Moller LB, Paulsen M, Koch R, Moats R, Guldberg P, Guttler F. Inter-individual variation in brain phenylalanine concentration in patients with PKU is not caused by genetic variation in the 4F2hc/LAT1 complex. Mol Genet Metab. 2005; 86 Suppl 1: S119-23.
90. Weglage J, Wiedermann D, Denecke J, Feldmann R, Koch HG, Ullrich K, et al. Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria. Ann Neurol. 2001; 50(4): 463-7.
91. Koch R, Moats R, Guttler F, Guldberg P, Nelson Jr M. Blood-brain phenylalanine relationships in persons with phenylketonuria. Pediatrics. 2000; 106(5): 1093-6.
92. Hawkins RA, O'Kane RL, Simpson IA, Vina JR. Structure of the blood-brain barrier and its role in the transport of amino acids. J Nutr. 2006; 136(1 Suppl): 218S-26S.
93. Christensen HN. Metabolism of amino acids and proteins. Annu Rev Biochem. 1953; 22: 233-60.
94. Christensen HN, Streicher JA, Elbinger RL. Effects of feeding individual amino acids upon the distribution of other amino acids between cells and extracellular fluid. J Biol Chem. 1948; 172(2): 515-24.
95. Surtees R, Blau N. The neurochemistry of phenylketonuria. Eur J Pediatr. 2000; 159 Suppl 2: S109-13.
96. Andersen AE, Avins L. Lowering brain phenylalanine levels by giving other large neutral amino acids: a new experimental therapeutic approach to phenylketonuria. Arch Neurol. 1976; 33(10): 684-6.
97. Pietz J, Kreis R, Rupp A, Mayatepek E, Rating D, Boesch C, et al. Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria. J Clin Invest. 1999; 103(8): 1169-78.
98. Matalon R, Surendran S, Matalon KM, Tyring S, Quast M, Jinga W, et al. Future role of large neutral amino acids in transport of phenylalanine into the brain. Pediatrics. 2003; 112(6): 1570-4.
99. Matalon R, Michals-Matalon K, Bhatia G, Grechanina E, Novikov P, McDonald JD, et al. Large neutral amino acids in the treatment of phenylketonuria (PKU). J Inherit Metab Dis. 2006; 29(6): 732-8.
100. Matalon R, Michals-Matalon K, Bhatia G, Burlina AB, Burlina AP, Braga C, et al. Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine. J Inherit Metab Dis. 2007; 30(2): 153-8.
101. van Spronsen FJ, de Groot MJ, Hoeksma M, Reijngoud DJ, van Rijn M. Large neutral amino acids in the treatment of PKU: from theory to practice. J Inherit Metab Dis. 2010; 33(6): 671-6.
102. Schindeler S, Ghosh-Jerath S, Thompson S, Rocca A, Joy P, Kemp A, et al. The effects of large neutral amino acid supplements in PKU: an MRS and neuropsychological study. Mol Genet Metab. 2007; 91(1): 48-54.
103. Ney DM, Gleason ST, van Calcar SC, MacLeod EL, Nelson KL, Etzel MR, et al. Nutritional management of PKU with glycomacropeptide from cheese whey. J Inherit Metab Dis. 2009; 32(1): 32-9.
104. Etzel MR. Manufacture and use of dairy protein fractions. J Nutr. 2004; 134(4): 996s-1002s.
105. Ney DM, MacLeod EL, Clayton MK, van Calcar SC. Breakfast with glycomacropeptide compared with amino acids suppresses plasma ghrelin levels in individuals with phenylketonuria. Mol Genet Metab. 2010; 100(4): 303-8.
106. MacDonald A, Rylance G, Davies P, Asplin D, Hall SK, Booth IW. Administration of protein substitute and quality of control in phenylketonuria: a randomized study. J Inherit Metab Dis. 2003; 26(4): 319-26.
107. Ney DM, van Calcar SC, MacLeod EL, Gleason ST, Etzel MR, Clayton MK, et al. Improved nutritional management of phenylketonuria by using a diet containing glycomacropeptide compared with amino acids. Am J Clin Nutr. 2009; 89(4): 1068-77.
108. Vajro P, Strisciuglio P, Houssin D, Huault G, Laurent J, Alvarez F, et al. Correction of phenylketonuria after liver-transplantation in a child with cirrhosis. New Engl J Med. 1993; 329(5): 363.
109. Ledley FD, Grenett HE, Dilella AG, Kwok SCM, Woo SLC. Gene-transfer and expression of human phenylalanine-hydroxylase. Science. 1985; 228(4695): 77-9.
110. Liu TJ, Kay MA, Darlington GJ, Woo SL. Reconstitution of enzymatic activity in hepatocytes of phenylalanine hydroxylase-deficient mice. Somat Cell Mol Genet. 1992; 18(1): 89-96.
111. Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W, et al. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther. 1994; 1(4): 247-54.
112. Harding CO, Gillingham MB, Hamman K, Clark H, Goebel-Daghighi E, Bird A, et al. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria. Gene Ther. 2006; 13(5): 457-62.
113. Laipis PJ, Charron CE, Embury JE, Perera OP, Porvasnik SL, Fields CR, et al. Correction of maternal phenylketonuria syndrome in the Pah(enu2) missense mutant mouse by r-AAV mediated gene therapy. Mol Ther. 2004; 9: S334.
114. Mochizuki S, Mizukami H, Ogura T, Kure S, Ichinohe A, Kojima K, et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Ther. 2004; 11(13): 1081-6.
115. Jacobs F, Wang L. Adeno-associated viral vectors for correction of inborn errors of metabolism: progressing towards clinical application. Curr Pharm Des. 2011; 17(24): 2500-15.
116. Kay MA, Nakai H. Looking into the safety of AAV vectors. Nature. 2003; 424(6946): 251.
117. Shedlovsky A, Mcdonald JD, Symula D, Dove WF. Mouse models of human phenylketonuria. Genetics. 1993; 134(4): 1205-10.
118. Cristiano RJ, Smith LC, Woo SL. Hepatic gene therapy: adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sci USA. 1993; 90(6): 2122-6.
119. Davidoff AM, Ng CYC, Zhou JF, Spence Y, Nathwani AC. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood. 2003; 102(2): 480-8.
120. Ding Z, Georgiev P, Thony B. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer. Gene Ther. 2006; 13(7): 587-93.
121. Rebuffat A, Thony B, Harding CO, Ding ZB. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum Gene Ther. 2010; 21(4): 463-77.
122. Yagi H, Kume A, Ogura T, Mizukami H, Urabe M, Hamada H, et al. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector. J Gene Med. 2011; 13(2): 114-22.
123. Harding CO, Wild K, Chang D, Messing A, Wolff JA. Metabolic engineering as therapy for inborn errors of metabolism-development of mice with phenylalanine hydroxylase expression in muscle. Gene Ther. 1998; 5(5): 677-83.
124. Ding Z, Harding CO, Rebuffat A, Elzaouk L, Wolff JA, Thony B. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system. Mol Ther. 2008; 16(4): 673-81.
125. Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP, Spitler R, Flores MA, Leake D, et al. Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD). Mol Ther. 2010; 18(9): 1667-74.
126. Pearton M, Allender C, Brain K, Anstey A, Gateley C, Wilke N, et al. Gene delivery to the epidermal cells of human skin explants using microfabricated microneedles and hydrogel formulations. Pharm Res. 2008; 25(2): 407-16.
127. Jensen DM, Cun D, Maltesen MJ, Frokjaer S, Nielsen HM, Foged C. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release. 2010; 142(1): 138-45.
128. Eavri R, Lorberboum-Galski H. A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria. J Biol Chem. 2007; 282(32): 23402-9.
129. Pentchev PG, Brady RO, Gal AE, Hibbert SR. Replacement therapy for inherited enzyme deficiency-sustained clearance of accumulated glucocerebroside in gauchers-disease following infusion of purified glucocerebrosidase. J Mol Med. 1975; 1(1): 73-8.
130. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA. 1990; 87(5): 1913-6.
131. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease. New Engl J Med. 2001; 345(1): 9-16.
132. Coman DJ, Hayes IM, Collins V, Sahhar M, Wraith JE, Delatycki MB. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families. J Pediatr. 2008; 152(5): 723-7.
133. Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004; 144(5): 574-80.
134. van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, et al. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics. 2004; 113(5): e448-57.
135. Brady RO. Enzyme replacement for lysosomal diseases. Annu Rev Med. 2006; 57: 283-96.
136. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3): 214-21.
137. Erlandsen H, Patch MG, Gamez A, Straub M, Stevens RC. Structural studies on phenylalanine hydroxylase and implications toward understanding and treating phenylketonuria. Pediatrics. 2003; 112(6 Pt 2): 1557-65.
138. Gamez A, Wang L, Straub M, Patch MG, Stevens RC. Toward PKU enzyme replacement therapy: PEGylation with activity retention for three forms of recombinant phenylalanine hydroxylase. Mol Ther. 2004; 9(1): 124-9.
139. Bourget L, Chang TM. Phenylalanine ammonia-lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. Biochim Biophys Acta. 1986; 883(3): 432-8.
140. Ambrus CM, Ambrus JL, Horvath C, Pedersen H, Sharma S, Kant C, et al. Phenylalanine depletion for management of phenylketonuria-use of enzyme reactors with immobilized enzymes. Science. 1978; 201(4358): 837-9.
141. Kaufman S. Phenylketonuria and its variants. Adv Hum Genet. 1983; 13: 217-97.
142. Xiang LK, Moore BS. Biochemical characterization of a prokaryotic phenylalanine ammonia lyase. J Bacteriol. 2005; 187(12): 4286-9.
143. Koukol J, Conn EE. Metabolism of aromatic compounds in higher plants. IV. Purification and properties of phenylalanine deaminase of Hordeum vulgare. J Biol Chem. 1961; 236(10): 2692-8.
144. Sikora LA, Marzluf GA. Regulation of l-phenylalanine ammonia-lyase by l-phenylalanine and nitrogen in Neurospora crassa. J Bacteriol. 1982; 150(3): 1287-91.
145. Hodgins DS. Yeast phenylalanine ammonia-lyase. Purification, properties, and the identification of catalytically essential dehydroalanine. J Biol Chem. 1971; 246(9): 2977-85.
146. Marusich WC, Jensen RA, Zamir LO. Induction of l-phenylalanine ammonia-lyase during utilization of phenylalanine as a carbon or nitrogen-source in Rhodotorula glutinis. J Bacteriol. 1981; 146(3): 1013-9.
147. Orndorff SA, Costantino N, Stewart D, Durham DR. Strain improvement of Rhodotorula graminis for production of a novel L-phenylalanine ammonia lyase. Appl Environ Microb. 1988; 54(4): 996-1002.
148. Fritz RR, Hodgins DS, Abell CW. Phenylalanine ammonia-lyase-induction and purification from yeast and clearance in mammals. J Biol Chem. 1976; 251(15): 4646-50.
149. Snapper I, Yu TF, Chiang YT. Cinnamic acid metabolism in man. P Soc Exp Biol Med. 1940; 44: 30-4.
150. Hoskins JA, Gray J. Phenylalanine ammonia-lyase in the management of phenylketonuria-the relationship between ingested cinnamate and urinary hippurate in humans. Res Commun Chem Path. 1982; 35(2): 275-82.
151. Shen RS, Fritz RR, Abell CW. Clearance of phenylalanine ammonia-lyase from normal and tumor-bearing mice. Cancer Res. 1977; 37(4): 1051-6.
152. Bourget L, Chang TMS. Phenylalanine ammonia-lyase immobilized in microcapsules for the depletion of phenylalanine in plasma in phenylketonuric rat model. Biochimica Et Biophysica Acta. 1986; 883(3): 432-8.
153. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery. Drug Discov Today. 2006; 11(19-20): 905-10.
154. Hamman JH, Enslin GM, Kotze AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs. 2005; 19(3): 165-77.
155. Bourget L, Chang TM. Phenylalanine ammonia-lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria. FEBS Lett. 1985; 180(1): 5-8.
156. Habibi-Moini S, D'mello AP. Evaluation of possible reasons for the low phenylalanine ammonia lyase activity in cellulose nitrate membrane microcapsules. Int J Pharm. 2001; 215(1-2): 185-96.
157. Shah RM, D'mello AP. Strategies to maximize the encapsulation efficiency of phenylalanine ammonia lyase in microcapsules. Int J Pharm. 2008; 356(1-2): 61-8.
158. Figlewicz DA, Druse MJ. Experimental hyperphenylalaninemia: effect on central nervous system myelin subfractions. Exp Neurol. 1980; 67(2): 315-29.
159. McDonald JD, Bode VC, Dove WF, Shedlovsky A. The use of N-ethyl-N-nitrosourea to produce mouse models for human phenylketonuria and hyperphenylalaninemia. Prog Clin Biol Res. 1990; 340 C: 407-13.
160. Safos S, Chang TM. Enzyme replacement therapy in ENU2 phenylketonuric mice using oral microencapsulated phenylalanine ammonia-lyase: a preliminary report. Artif Cells Blood Substit Immobil Biotechnol. 1995; 23(6): 681-92.
161. Evans CT, Hanna K, Conrad D, Peterson W, Misawa M. Production of phenylalanine ammonia-lyase (PAL)-isolation and evaluation of yeast strains suitable for commercial production of l-phenylalanine. Appl Microbiol Biot. 1987; 25(5): 406-14.
162. Orum H, Rasmussen OF. Expression in Escherichia coli of the gene encoding phenylalanine ammonia-lyase from Rhodosporidium toruloides. Appl Microbiol Biot. 1992; 36(6): 745-8.
163. Sarkissian CN, Shao Z, Blain F, Peevers R, Su H, Heft R, et al. A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc Natl Acad Sci USA. 1999; 96(5): 2339-44.
164. Sarkissian CN, Boulais DM, McDonald JD, Scriver CR. A heteroallelic mutant mouse model: a new orthologue for human hyperphenylalaninemia. Mol Genet Metab. 2000; 69(3): 188-94.
165. Wang L, Gamez A, Sarkissian CN, Straub M, Patch MG, Won Han G, et al. Structure-based chemical modification strategy for enzyme replacement treatment of phenylketonuria. Mol Genet Metab. 2005; 86(1-2): 134-40.
166. Gamez A, Sarkissian CN, Wang L, Kim W, Straub M, Patch MG, et al. Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria. Mol Ther. 2005; 11(6): 986-9.
167. Ikeda K, Schiltz E, Fujii T, Takahashi M, Mitsui K, Kodera Y, et al. Phenylalanine ammonia-lyase modified with polyethylene glycol: potential therapeutic agent for phenylketonuria. Amino Acids. 2005; 29(3): 283-7.
168. Moffitt MC, Louie GV, Bowman ME, Pence J, Noel JP, Moore BS. Discovery of two cyanobacterial phenylalanine ammonia lyases: kinetic and structural characterization. Biochemistry. 2007; 46(4): 1004-12.
169. Wang L, Gamez A, Archer H, Abola EE, Sarkissian CN, Fitzpatrick P, et al. Structural and biochemical characterization of the therapeutic Anabaena variabilis phenylalanine ammonia lyase. J Mol Biol. 2008; 380(4): 623-35.
170. Sarkissian CN, Gamez A, Wang L, Charbonneau M, Fitzpatrick P, Lemontt JF, et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc Natl Acad Sci USA. 2008; 105(52): 20894-9.
171. Kang TS, Wang L, Sarkissian CN, Gamez A, Scriver CR, Stevens RC. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria. Mol Genet Metab. 2010; 99(1): 4-9.
172. Sarkissian CN, Kang TS, Gamez A, Scriver CR, Stevens RC. Evaluation of orally administered PEGylated phenylalanine ammonia lyase in mice for the treatment of phenylketonuria. Mol Genet Metab. 2011; 104(3): 249-54.
173. Liu J, Jia X, Zhang J, Xiang H, Hu W, Zhou Y. Study on a novel strategy to treatment of phenylketonuria. Artif Cells Blood Substit Immobil Biotechnol. 2002; 30(4): 243-57.
174. Zhang YL, Wang LY, Jia XY, Liu JZ, Ma GH. Preparation of Ca-alginate microparticles and its application for phenylketonuria oral therapy. Ind Eng Chem Res. 2011; 50(7): 4106-12.
175. Dubey S, Kalia YN. Electrically-assisted delivery of an anionic protein across intact skin: cathodal iontophoresis of biologically active ribonuclease T1. J Control Release. 2011; 152(3): 356-62.
176. Kim Y-C, Prausnitz M. Enabling skin vaccination using new delivery technologies. Drug Deliv Transl Res. 2011; 1(1): 7-12.
177. Depreter F, Amighi K. Formulation and in vitro evaluation of highly dispersive insulin dry powder formulations for lung administration. Eur J Pharm Biopharm. 2010; 76(3): 454-63.
178. Mudaliar S. Inhaled insulin using AERx insulin diabetes management system (AERx iDMS). Expert Opin Invest Drugs. 2007; 16(10): 1673-81.